Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience

by Elbedewy TA, Elsebaey MA, Elkholy RA, Tahoon DM, Elshweikh SA
Published 2020-12-01

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

by Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S
Published 2019-02-01

Galectin-3 as a prognostic biomarker for diabetic nephropathy

by Hodeib H, Hagras MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, Elsebaey MA, Elshweikh SA
Published 2019-03-01

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

by Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S
Published 2018-03-01